You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

302 Results
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Obinutuzumab - In Combination with Chemotherapy for Refractory Follicular Lymphoma
ODB - General Benefit
    prednisone
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
oBINutuzumab,
prednisone,
vinCRIStine,
DOXOrubicin,
cyclophosphamide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Nov 2023
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Inotuzumab Ozogamicin (Outpatient) - Relapsed or Refractory Acute Lymphoblastic Leukemia
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
inotuzumab ozogamicin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jul 2023
Regimen
Cancer Type:
Breast, 
Central Nervous System, 
Gastrointestinal, 
Colorectal, 
Esophagus, 
Gastric / Stomach, 
Hepatobiliary / Liver / Bile Duct, 
Pancreas, 
Genitourinary, 
Bladder / Urothelial, 
Prostate, 
Gynecologic, 
Cervix, 
Endometrial, 
Ovary, 
Head and Neck, 
Lung, 
Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Curative, Palliative
Drugs Used:
CARBOplatin,
irinotecan
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Dec 2023
Regimen
Cancer Type:
Gastrointestinal, 
Neuroendocrine (GI)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
irinotecan,
leucovorin,
fluorouracil
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Apr 2023
Regimen
Cancer Type:
Gastrointestinal, 
Anus
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
DOCEtaxel,
CISplatin,
fluorouracil
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Apr 2023
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
oxaliplatin,
leucovorin,
fluorouracil
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Apr 2023
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant
Funding:
New Drug Funding Program
    Trastuzumab Emtansine - Adjuvant Treatment for Early Breast Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
Kadcyla trastuzumab emtansine
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Oct 2023
Drug
Other Name(s): Besponsa®
Quick Link(s): Drug Monograph, Patient Info Sheet
Jul 2023
Drug
Other Name(s): Folotyn®
Quick Link(s): Drug Monograph, Patient Info Sheet
Dec 2021
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - In Combination with Carboplatin and Paclitaxel for First-Line Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
pembrolizumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jan 2023
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative, Adjuvant
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
fluorouracil,
EPIrubicin,
cyclophosphamide,
DOCEtaxel,
PERTuzumab (Unfunded),
trastuzumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Apr 2023
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    aXitinib - In combination with pembrolizumab for first-line advanced or metastatic renal cell carcinoma
New Drug Funding Program
    Pembrolizumab - In Combination with Axitinib for First Line Advanced or Metastatic Renal Cell Carcinoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
aXitinib,
pembrolizumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2023

Pages